Literature DB >> 8388622

Gadopentetate dimeglumine as an alternative contrast material for use in angiography.

Y Kinno1, K Odagiri, K Andoh, Y Itoh, K Tarao.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388622     DOI: 10.2214/ajr.160.6.8388622

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


× No keyword cloud information.
  6 in total

1.  A new technique for localization of hepatic tumors that are poorly visible with CT fluoroscopy.

Authors:  Lionel Arrivé; Olivier Rosmorduc; Louisa Azizi; Laurence Monnier-Cholley; Maïté Lewin; Marc Beaussier; Jean-Michel Tubiana
Journal:  Eur Radiol       Date:  2006-04-19       Impact factor: 5.315

2.  Intraindividual comparison of gadolinium- and iodine-enhanced 64-slice multidetector CT pulmonary angiography for the detection of pulmonary embolism in a porcine model.

Authors:  Frank Oliver Gerhard Henes; Michael Groth; Philipp G C Begemann; Gerhard Adam; Marc Regier
Journal:  Emerg Radiol       Date:  2010-12-07

3.  Gadopentetate dimeglumine as a contrast agent in common carotid arteriography.

Authors:  W K Erly; J Zaetta; G T Borders; H Ozgur; D R Gabaeff; R F Carmody; J Seeger
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 3.825

4.  One-molar gadolinium chelate (gadobutrol) as a contrast agent for CT angiography of the thoracic and abdominal aorta.

Authors:  José M Esteban; Antonio Alonso; Vicente Cervera; Vicente Martínez
Journal:  Eur Radiol       Date:  2007-02-07       Impact factor: 5.315

Review 5.  Actual clinical use of gadolinium-chelates for non-MRI applications.

Authors:  Holger M Strunk; H Schild
Journal:  Eur Radiol       Date:  2004-02-10       Impact factor: 5.315

6.  Arterial angiography in high-kilovoltage technique with gadolinium as the contrast agent: first clinical experience.

Authors:  F Fobbe; F Wacker; S Wagner
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.